Hormone treatment

In breast cancer patients, total PR status is measured for hormonal treatment. The presence of PR is associated with increased survival rates and hormonal responsiveness of mammary tumors. PR agonists are widely used in contraception, HRT, breast cancer, and endometrial hyperplasia. Antiprogestins such as RU486 are used for blocking ovulation and preventing implantation, and in addition they are in clinical testing for the induction of labor and to control various neoplastic transformations. [Pg.1130]

If treatment with an SSRI or another antidepressant such as clomipramine is not successful, hormonal treatment with a GnRH agonist, such as leuprolide, maybe considered. The use of leuprolide improves premenstrual emotional symptoms as well as some physical symptoms such as bloating and breast tenderness. Cost, the need for intramuscular administration, and the side effects of hypoestrogenism (e.g., vaginal dryness and hot flashes) limit its use. [Pg.762]

However, colorectal cancer and rates of fracture were reduced with combined hormonal treatment. [Pg.766]

In summary, combined estrogen plus progestin should not be used for the prevention of chronic diseases because it increases the risk of CHD, stroke, breast cancer, and venous thromboembolism. However, colorectal cancer and rates of fracture were reduced with combined hormonal treatment. [Pg.773]

Assess the patient for use of HRT by evaluating for the presence of vasomotor symptoms. If the patient is experiencing bothersome vasomotor symptoms, consider the use of HRT only after assessing for risk factors for heart disease and breast cancer. If vasomotor symptoms are tolerable and/or the patient has risk factors for heart disease and/or breast cancer, consider alternative, non-hormonal treatments for vasomotor symptoms. [Pg.776]

Hormonal therapies have shown activity in the treatment of cancers whose growth is affected by gonadal hormonal control. Hormonal treatments either block or decrease the production of endogenous hormones. [Pg.1295]

Androgen independence is a common feature of prostate cancer progression. CXCR1 expression and the emergence of androgen independence were examined in prostate cancer specimens from patients undergoing hormonal treatment... [Pg.341]

Most women with vasomotor symptoms need hormone treatment for less than 5 years. Without treatment, hot flushes usually disappear within 1 to 2 years. Hormone therapy can usually be tapered and stopped after about 2 or 3 years. [Pg.360]

Local treatment should be offered to all women, especially those not receiving hormone treatment. Urogenital atrophy and vaginal dryness is frequent, but women have difficulties in expressing these symptoms, which is why the clinician should address this issue systematically. [Pg.352]

During the symptomatic window, beginning even before menopause, hormonal treatment remains the best alternative, administered at the adequate... [Pg.352]

There may be a significant negative correlation between endogeneous testosterone and Lp(a) levels in man (DIO), while, on the other hand, growth hormone treatment increases Lp(a) levels (E6, 02). [Pg.91]

E6. Eden, S., Wiklund, O., Oscarsson, J., Rosen, T., and Bengtsson, B. A., Growth hormone treatment of growth hormone deficient adults results in a marked increase in lipoprotein(a) and HDL-cholesterol concentration. Atheroscler. Thromb. 13, 296-301 (1993). [Pg.116]

Olivecrona, H., Ericsson, S., Berglund, L., and Angelin, B., Increased concentration of serum lipoprotein(a) in response to growth hormone treatment. BMJ 306, 1726-1727 (1993). [Pg.127]

Three isoenzymes of carboxylesterase were purified from rat liver micro-somes and were named RL1, RL2, and RH1. These differ from each other in their response to hormone treatment, inducibility, substrate specificity, and immunological properties [75], It was shown that RL1, RL2, and RH1 resemble hydrolases p/ 6.2/6.4, pI 6.0, and pI 5.6, respectively. Enzyme RL2 was found to be identical to egasyn, a protein with esterase activity found in the endoplasmic reticulum [76], The role of egasyn is to stabilize glucuronidase (EC 3.2.1.31) by noncovalent binding to the microsomal membrane. [Pg.47]

Thyroid Hormone Receptor (TR) can bind to the LTR in vivo independently of its ligand and regulates promoter activity. ChIP assays with anti-acetylated-histone antibodies revealed that unliganded TR reduce the local histone acetylation levels at the HIV-1 LTR, while thyroid hormone treatment reverses this induction (Hsia and Shi, 2002). Accordingly, unliganded TR recruits co repressors and at least one HDAC (Hsia and Shi, 2002). [Pg.379]

Other Medications. A variety of other medications have been tried. These include hormone treatments and certain blood pressure medications (e.g., clonidine and the beta blockers). For the most part, these have met with minimal success and should not be considered a part of routine treatment. [Pg.303]

Tamoxifen is an oestrogen-receptor antagonist indicated as adjuvant hormonal treatment in oestrogen-receptor-positive breast cancer in postmenopausal women. Common side-effects include alopecia and uterine fibroids. [Pg.81]

See, John T. Melella et at. Legal and Ethical Issues in the Use of Antiandrogens in Treating Sex Offenders, 17 BULL. AM. ACAD. PSYCHIATRY L. 223,225 (1989) John McD. W. Bradford, The Hormonal Treatment of Sexual Offenders, 11 BULL. AM. ACAD. PSYCHIATRY L. 159, 163(1983). [Pg.47]

Under this therapy, menses will continue. The risk of thromboembolic disorders is increased and that of myocardial infarction probably lowered. Hormone treatment can be extended for 10 y or longer. Before menopause, daily calcium intake should be kept at 1 g (contained in 1 L of milk), and 1.5 g thereafter. [Pg.318]

Thyroid-Releasing Hormone Toxic Substances Control Act Thyroid Stimulating Hormone Treatment Technique Threshold of Toxicological Concern Target-organ Toxicity dose Unscheduled DNA Synthesis Uncertainty Factor United Nations... [Pg.449]

Congenital defects in the biosynthesis of steroid hormones can lead to severe developmental disturbances, in the adrenogenital syndrome (AGS), which is relatively common, there is usually a defect in 21-hydroxylase, which is needed for synthesis of cortisol and aldosterone from progesterone. Reduced synthesis of this hormone leads to increased formation of testosterone, resulting in masculin-ization of female fetuses. With early diagnosis, this condition can be avoided by providing the mother with hormone treatment before birth. [Pg.376]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...